Interleukin-22 promotes cancer stemness and chemotherapy resistance in colorectal cancer via epidermal growth factor receptor/extracellular signal-regulated kinase pathway

Figure 2 Interleukin-22 treatment attenuates the cytotoxic and apoptosis-inducing effects of oxaliplatin in colorectal cancer cells. A: Cell viability under increasing concentrations of oxaliplatin (L-OHP) (0-25 μg/mL) in the presence of interleukin-22 (IL-22) (5 ng/mL and 50 ng/mL); B: Half maximal inhibitory concentration (IC₅₀) of L-OHP with or without IL-22 treatment; C: Cell viability in control, IL-22, L-OHP, and IL-22 + L-OHP groups assessed by MTT assay; D: Flow cytometry analysis of apoptosis in the same four groups. Data are represented as mean ± SE (n = 3). Statistical analysis was performed using one-way analysis of variance followed by Tukey’s post hoc test. ^aP < 0.01 vs PBS or Control group; ^bP < 0.01 vs L-OHP group. L-OHP: Oxaliplatin; IL-22: Interleukin-22; IC₅₀: Half maximal inhibitory concentration.